Study of Tarperprumig for ANCA-associated vasculitis
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a new drug (tarperprumig) for people with active ANCA-associated vasculitis (GPA or MPA). The goal is to see if it is safe and effective for treating the disease, especially when standard treatments like rituximab or cyclophosphamide are being considered.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of vasculitis called GPA (granulomatosis with polyangiitis) or MPA (microscopic polyangiitis) that is either newly diagnosed or has come back after treatment.
- You have tested positive for ANCA antibodies (PR3 or MPO) in the past or at the screening visit.
- You have active disease symptoms that need treatment, like significant kidney problems, lung, or other organ issues.
- You do not have other types of vasculitis or autoimmune diseases as the main cause of your illness, such as lupus, EGPA, or anti-GBM disease.
- You do not have severe lung bleeding that requires a breathing machine at the time of screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called NM8074 for people with ANCA-associated vasculitis, a condition where the immune system attacks blood vessels. It aims to see if the drug can help control the disease when used with standard treatments like cyclophosphamide or rituximab.
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
This trial compares two strategies for people with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) who have stable disease but whose ANCA blood test has become positive again. The goal is to see whether waiting and monitoring closely works as well as giving a pre-emptive dose of rituximab to prevent a flare.
This study tests an oral medication called avacopan for people with active ANCA-associated vasculitis (GPA or MPA). It’s for those who need strong treatment to control their disease and aims to see if avacopan works as well as standard therapies.
This trial tests a new CAR T-cell therapy (CC-97540) for people with active ANCA vasculitis (GPA or MPA) that has not responded to or has returned after standard treatments. The goal is to see if this personalized cell therapy can calm the immune system and reduce disease activity.
Hear when a new Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.